Overview

Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis

Status:
Completed
Trial end date:
1998-09-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Compare the safety and efficacy of monolaurin cream versus a placebo vehicle cream in suppressing the signs of nonbullous congenital ichthyosiform erythroderma. II. Assess the incidence of posttreatment rebound or recrudescence in patients with congenital ichthyosis. III. Evaluate the long term safety of monolaurin cream with whole body application in these patients.
Phase:
Phase 3
Details
Lead Sponsor:
Cellegy Pharmaceuticals
Treatments:
Monolaurin